Trinity Biotech (TRIB) has released an update.
Trinity Biotech plc has announced significant progress in the development of their next-generation continuous glucose monitor (CGM) technology, which includes a novel European-patented method to enhance glucose biosensor performance. This advancement promises to reduce the sensor’s run-in time and improve its accuracy, positioning the company to introduce an optimized CGM device into the global market. The technology aims to create a more user-friendly, self-calibrating device, eliminating the need for periodic re-calibration with separate blood glucose monitors.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.
